版本:
中国

BRIEF-Contravir’S Cyclophilin inhibitor CRV431 targets hepatitis B surface antigen (HBSAG)

April 4 Contravir Pharmaceuticals Inc

* Contravir’S Cyclophilin inhibitor CRV431 targets hepatitis B surface antigen (HBSAG)

* New studies show that CRV431 potently blocks interaction between hepatitis B surface antigen and Cyclophilin A

* New information could explain previous findings that CRV431 reduces HBSAG in many experimental systems

* Findings further elucidate MOA of CRV431, and support contravir's strategy of providing a "functional cure" Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐